Filing follows release of positive Phase 3 study results for zalunfiban (DisaggproTM); company also appoints Chief Commercial Officer DEL MAR, Calif., June 24, 2026 /PRNewswire/ -- CeleCor Therapeutics has submitted the final section of its New Drug Application for the company's...
Hence then, the article about celecor completes submission of fda new drug application for investigational heart attack drug was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG )
Also on site :
- Our Legacy Spring 2027 Ready-to-Wear Collection
- Walmart's 'Quality' $43 5-Tier Garden Bed Is 'Sturdy,' 'Functional,' and Perfect for Small Outdoor Spaces
- Laneige’s 'Buttery-Smooth' Lip Balm Is a 'Hydrating' K-Beauty Staple That's 40% Off for Amazon Prime Day